

## **Agios Pharmaceuticals**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 09-Jul-2013

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drugs..... 9

[Return to Table of Contents](#)

# Agios Pharmaceuticals

## COMPANY OVERVIEW

<b>Company Name</b>	Agios Pharmaceuticals
<b>Parent Company Name</b>	Agios Pharmaceuticals
<b>Website</b>	<a href="http://www.agios.com/">http://www.agios.com/</a>
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	4
<b>Number of Inactive Drugs</b>	1
<b>Number of Patents as Owner</b>	21
<b>Number of Patents as Third Party</b>	1
<b>Number of Deals</b>	8
<b>Key Indications</b>	Cancer, Inborn error of metabolism, Sickle cell anemia, Acute myelogenous leukemia, Colon tumor, Hemolytic anemia, Cholangiocarcinoma, Chondrosarcoma, Glioblastoma, Melanoma, Myelo dysplastic syndrome, Myeloproliferative disorder, Non-small-cell lung
<b>Key Target-based Actions</b>	Isocitrate dehydrogenase inhibitor, Pyruvate kinase muscle isozyme inhibitor, Pyruvate kinase muscle isozyme stimulator, IDH1 gene inhibitor, Cytoplasmic isocitrate dehydrogenase inhibitor, Pyruvate kinase stimulator, Pyruvate kinase 2 modulator, AMP activated protein kinase stimulator, Cytoplasmic isocitrate dehydrogenase modulator, EGFR gene modulator, IDH1 gene modulator, IDH2 gene inhibitor, IDH2 gene modulator, KRAS gene modulator, Mitochondrial isocitrate dehydrogenase inhibitor, Mitochondrial isocitrate dehydrogenase modulator, Pyruvate kinase 2 stimulator, Pyruvate kinase muscle isozyme modulator
<b>Key Technologies</b>	Small molecule therapeutic, Drug screening, Enzyme, Analytical method, Animal model, Chromatography analytical, DNA sequencing technology, Diagnostic method, Fluorescence, Immunodetection, Luminescence, Spectrometry

## COMPANY PROFILE

### SUMMARY

Agios Pharmaceuticals, founded as part of a seed financing by ARCH Venture Partners and Flagship Ventures, is a biopharmaceutical company focused on the development of therapeutics which target key metabolic pathways in order to disrupt the growth and survival of cancer cells.

### COMPANY LOCATION

In November 2008, Agios opened a 21,000 sq ft state-of-the-art laboratory dedicated to cancer metabolism research in Cambridge, MA.

### LICENSING AGREEMENTS

In December 2009, ABC2 (Accelerate Brain Cancer Cure) provided funding to Agios Pharmaceuticals for the development of IDH1 therapeutics and diagnostics in brain cancer (glioma). Agios received undisclosed funding.

### FINANCIAL

In November 2011, Agios raised \$78 million from an oversubscribed series C financing.

In July 2008, Agios raised \$33 million from a series A financing round. Proceeds would be used to advance development of the company's pipeline.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	1	4
Genetic disorder	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Discovery	4
No Development Reported	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	1	0	1
Patent - Exclusive Rights	0	0	1	0	1
Drug - Funding	2	0	0	0	2
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	1	0	1	0	2
Drug - Development Services	0	0	1	0	1

[Return to Table of Contents](#)

## PATENTS \*

Indication	As Owner	As Third Party	Total
Endocrine disease	1	0	1
Gastrointestinal disease	4	0	4
Genitourinary disease	2	0	2
Hematological disease	9	0	9
Andrology	2	0	2
Musculoskeletal disease	3	0	3
Neoplasm	16	1	17
Genetic disorder	5	0	5
Neurological disease	1	0	1
Respiratory disease	3	0	3
Gynecology and obstetrics	1	0	1
Dermatological disease	2	0	2

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)





## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### PKM2 inhibitors (cancer), Agios/Celgene

<b>Drug Name</b>	PKM2 inhibitors (cancer), Agios/Celgene
<b>Key Synonyms</b>	
<b>Originator Company</b>	Agios Pharmaceuticals
<b>Active Companies</b>	Celgene Corp, Agios Pharmaceuticals
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Pyruvate kinase muscle isozyme inhibitor
<b>Other Actions</b>	Anticancer, Glycolysis pathway modulator
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	21-Jun-2013

### IDH-1/IDH-2 inhibitors (cancer), Agios/Celgene

<b>Drug Name</b>	IDH-1/IDH-2 inhibitors (cancer), Agios/Celgene
<b>Key Synonyms</b>	
<b>Originator Company</b>	Agios Pharmaceuticals
<b>Active Companies</b>	Celgene Corp, Agios Pharmaceuticals
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Isocitrate dehydrogenase inhibitor
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	05-Apr-2013

[Return to Table of Contents](#)



### small molecule therapeutics (inborn errors of metabolism), Agios Pharmaceuticals

<b>Drug Name</b>	small molecule therapeutics (inborn errors of metabolism), Agios Pharmaceuticals
<b>Key Synonyms</b>	
<b>Originator Company</b>	Agios Pharmaceuticals
<b>Active Companies</b>	Agios Pharmaceuticals
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inborn error of metabolism
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	14-Feb-2013

### cancer metabolism inhibitors, Agios Pharmaceuticals

<b>Drug Name</b>	cancer metabolism inhibitors, Agios Pharmaceuticals
<b>Key Synonyms</b>	
<b>Originator Company</b>	Agios Pharmaceuticals
<b>Active Companies</b>	Agios Pharmaceuticals
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	14-Feb-2013

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

